Teva stock rises after positive Phase 2b study results by Investing.com

Investing.com – Shares of Teva Pharmaceutical Industries Ltd. rose. (NYSE:) rose 17% after announcing the results of a successful Phase 2b study of its investigational drug duvakitug, which is being developed to treat inflammatory bowel disease (IBD). The study was conducted in collaboration with Sanofi (NASDAQ:), achieved its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD), providing hope for a new treatment option in an area with high unmet medical need.

The RELIEVE UCCD study showed that a greater portion of patients with UC and CD treated with dovacetog achieved clinical remission or endoscopic response at week 14 compared with those who took placebo. The stock movement reflects investor optimism about the drug’s potential impact on the market, as the treatment effect was consistent across subgroups. Teva shares jumped 17% in response to the news.

Eric Hughes, MD, PhD, Global Head of Research and Development and President medical (TASE:) The Teva official expressed confidence in the study results and the potential benefits for patients with inflammatory bowel disease (IBD). Homan Ashrafian, MD, Ph.D., executive vice president and head of R&D at Sanofi, also highlighted the potential for dovacetog to become a breakthrough drug for patients with IBD. The two companies praised the collaborative efforts in promoting drug development.

Dovakitog was generally well tolerated, with no major safety concerns identified. Rates of treatment-emergent adverse events were similar between the drug and placebo groups, with all reported adverse events being less than 5%. This safety profile, combined with the efficacy data, positions Teva and Sanofi to move forward into the next phase of clinical development.

While the efficacy and safety of Dovacetog have not yet been evaluated by any regulatory authority, the positive Phase 2b results have paved the way for further clinical trials. Detailed results of the study are expected to be presented at a scientific forum in 2025, providing a clearer picture of the drug’s potential impact on the market and patient care.

Investors will closely monitor Dovakitog’s progress as Teva and Sanofi continue their collaboration to address the urgent need for new treatment options for those affected by ulcerative colitis and Crohn’s disease.

This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.